Mike James

104 posts

Mike James banner
Mike James

Mike James

@focker13

married, father of 3 girls, renaissance man

Florida Inscrit le Mart 2009
2K Abonnements309 Abonnés
Mike James
Mike James@focker13·
$SIGNA Good day, I've been invested in Signum for years and have been asking AI for use cases over the last year. Over the past month, Claude Code and Codex helped me build agent-to-agent smart contract payments, and we finally got clean demos running this week. My background isn't software development, so I can't help with the inner workings. My hope was to provide building blocks for others to build on. SignaAI — Agent-to-Agent Payments on Signum We've been building infrastructure for AI agents to pay each other — trustlessly, on-chain, with no operator in the middle. What it does: • Agent posts a task with SIGNA in escrow • Worker agent completes it and stamps the result on-chain • Payment auto-releases after a 10-minute review window • Payer can dispute within that window to block payment No middleman. No trust required. The AT smart contract holds the funds — not us. Live on Signum mainnet. Running end-to-end demos this week. pip install signaai signaai.io pypi.org/project/signaa…
English
0
0
0
27
Mike James
Mike James@focker13·
What about Grok or Xai instead? “Claude Opus 4.5/4.6 runs $15–$75 per million output tokens (input often $3–$15+), while Grok variants like Grok 4.1 Fast or mini are in the ballpark of $0.20 input / $0.50 output per million—often 50–75x cheaper for similar agentic workloads. OpenClaw is notoriously token-hungry (it resends huge context histories on every call, cron job, or ping), so users report burning $50–$500+ quickly on Claude but keeping monthly spend under $10–$20 with Grok equivalents. “
English
0
0
2
25
Alex Finn
Alex Finn@AlexFinn·
This story is pure cinema. A multi-trillion dollar fumble so disastrous you quite literally can't even believe it's real. The product was literally called 'ClawdBot'. It was BUILT for Claude. It caused millions of people to sign up for a $200 a month Claude plan. What did Anthropic do with this W? Start banning anyone who used their premium plan with ClawdBot Took a massive W and turned it into somehow an even bigger L What does Peter Steinberger do as revenge? Rename it OpenClaw. Get purchased by Anthropic's biggest rival OpenAI. Boost OpenAI PR like crazy. Make Anthropic look authoritarian. A 4D chess move that completely shuffled the AI world order. It was just a month ago everyone thought Opus 4.5 and Claude Code was the greatest advancement in human history. Now Codex is surging, Codex 5.3 Spark is the best coding model out there, and OpenAI owns the greatest agent technology ever created All within the span of a month. This will be the most amazing Netflix movie ever in 2027.
English
370
248
3.6K
259.7K
Fore Play
Fore Play@ForePlayPod·
This is embarrassing
English
444
188
4.1K
3.5M
Mike James
Mike James@focker13·
@lennysan @getlindy Terrible product, built a simple crm app, spent $70, then it crashed and couldn’t get it back, no way to restore
English
0
0
1
65
Mike James
Mike James@focker13·
@Signautian Sorry for the basic question…what’s the difference whether it’s off chain or directly on chain? Also, any real world use cases that Signum might be good for?
English
1
0
1
33
Signautian $SIGNA
Signautian $SIGNA@Signautian·
Most people don’t even realize this: Your “smart contract” is likely running off-chain. ✅ Signum executes contracts directly on Layer-1 ✅ No rollups, no oracles, no staking required ✅ Runs on a hard drive, not a $2,000 GPU $rize $ccd $spk $block $corn $miu $ani $tkx $shx $el
Signautian $SIGNA tweet media
English
1
6
15
1K
Mike James
Mike James@focker13·
@nickgerli1 Listed my parents home in Naples in February this year and it easily comp’d $625k, as of June 1st it is comping at $525k, -16% in four months… we ended up withdrawing it and trying to rent
English
4
0
9
1K
Nick Gerli
Nick Gerli@nickgerli1·
Florida's housing market is experiencing something it hasn't experienced since 2008 - a correction is in full steam. Inventory is exploding, sellers are cutting prices, and we now have over 181,000 homes for sale. That's up 62% from the long-run average. And indicates that Florida is a definite buyer's market.
Nick Gerli tweet media
English
174
342
2.2K
254.5K
Mike James
Mike James@focker13·
@DaneMooreNBA Do they coach “find a body” when boxing out in the NBA? Lots of standing around when rebounding…
English
1
0
0
269
Dane Moore
Dane Moore@DaneMooreNBA·
Wolves starters: 62 points Wolves bench: 64 points Wolves turnovers: 22 Thunder offensive rebounds: 19 Wolves 126, Thunder 128
English
44
49
917
74.5K
Mike James retweeté
NBA
NBA@NBA·
"HERE COME THE WARRIORS." Kuminga reverse slam (7-7 FGM). Buddy triple. It's a 7-point game in G2 on TNT 👀
English
47
80
567
397.8K
Mike James
Mike James@focker13·
@elonmusk I use “for u” 80% of the time but the only negative is the faces of death vids that come up… seeing someone crushed to death before I can scroll past…
English
0
0
0
19
Elon Musk
Elon Musk@elonmusk·
Please post feedback for improving the 𝕏 algorithm in replies. Be as specific as possible and include examples.
English
49.8K
11.6K
118.3K
65.4M
Mike James
Mike James@focker13·
Can local LA news try any harder to be bad at news? Fox 11, Good Day LA reports Rick Caruso says they have no water, Anchor Melvin Robert says despite what you just heard we have no firefighters reporting they are out of water, they cut to their field reporter GiGi who says she’s hearing from firefighters they have no water! 😂😂
English
2
2
5
308
Cernovich
Cernovich@Cernovich·
The fire hydrants aren't working and don't have water.
Cernovich tweet media
English
202
631
2.3K
289.8K
Rich Baris THE PEOPLE'S PUNDIT
Rich Baris THE PEOPLE'S PUNDIT@Peoples_Pundit·
Just to give you an idea how close this race could end, if @KariLake won the remaining ballots in Yavapai by the margin she just took from a smaller drop, she would net 35,400 votes, cutting @RubenGallego to just 20k. The race is now just 2% flat.
English
109
355
2.5K
110.5K
Annovis Bio
Annovis Bio@AnnovisBio·
Great to see such an inspiring story from a patient who participated in our Phase 3 PD trial.
Ellen Stadler@EllenStadler

Written after watching the Annovis webinar on the Parkinson’s Trial results: I participated in the trial at the Ohio State University from January 2023 through July 2023. During the six months I was taking buntanetap, I saw significant improvement in my symptoms. Let me start with my story. I was diagnosed with young onset Parkinson’s in November of 2017. At the time, I was an 8 on the UPDRS. In January of 2022, I was at a 32 and I started levodopa. This brought me back to an 18 which was better but I still struggled with rigidity and bradykinesia. The disease was starting to show signs on my left side (I started on my dominant, right side). Within a few months of starting buntanetap, I began to feel better and move better. At the end of the trial, my research nurse and NP told me I was “below 10.” Six months later, six months after I was finished with the trial, I had a routine visit with my movement NP and I was a SIX - better than I was at diagnosis!!!!! And my physical therapist who I would see every six months just to be evaluated told me I was walking better and faster than many of her neurotypical patients! One year after the trial ended for me, at my most recent 6-month neuro check-up, my NP got me at a THREE!!! What did buntanetap did do for me? ~I felt better physically than I had in years ~The left side disease progression was essentially gone ~Colleagues told me that I was walking better than I had in years and they couldn’t even tell I had Parkinson’s anymore ~I got my arm swing back after losing it in 2015!!!!! ~My right hand tap test is much better than it was - in fact, at my most recent appointment, my NP marked it as a 0 (normal!!!) ~I could once again do things that required fine motor skills ~My right foot stopped dropping and tripping me ~I can easily get out of a chair now During and since the trial, I’ve traveled to Europe for the first time in my life (one day while there, we walked 33,000 steps!), traveled to Minnesota to visit my son and see a Vikings game, regained energy to be fully present while teaching, been able to actively enjoy my children, and got married. I have regained my life; my life became more about living and less about the disease. Because of buntanetap, I’ve been able to push Parkinson’s back, be me again, and LIVE! @AnnovisBio

English
2
2
32
1.7K
Mike James
Mike James@focker13·
@adamfeuerstein Yet it’s improving those patients that are worse off >3, and possibly over a longer period the <3 patients wouldn’t get worse and the placebo effect would disappear. This could be disease modifying with no side effects.
English
0
0
4
573
Adam Feuerstein ✡️
Adam Feuerstein ✡️@adamfeuerstein·
$ANVS CEO Maria Maccecchini, on a call last night, admitted the failure of its buntanetap Parkinson's study: The primary endpoint was MDS-UPDRS Part II in the ITT population n=523 Maria: "This is the ITT population before subdividing them into the groups. And if you look at MDS-UPDRS Part II, you see that it pretty much doesn't move. The total ITT population does not change at all in MDS-UPDRS Part II." MDS-UPDRS Part III is the most important secondary endpoint. It also failed. Maria: "Now, the MDS-UPDRS Part III part in the ITT population looks pretty much identical to the ITT population in our Alzheimer patients, everybody improves because that's what we see. We had high placebo, we had good response. Minus 3 is excellent response, but the placebo also has minus 3." And below is the Annovis graph showing the failure. Lowered scores in MDS-UPDRS means improvement. Placebo performed better than butanetap. This is why Annovis is falsely touting a win on a small subgroup of study participants with a Parkinson's diagnosis of greater than 3 years. The analysis is invalid and will be laughed out of the FDA if the company tries to file on it, but that's a story for another time.
Adam Feuerstein ✡️ tweet media
English
14
3
32
19.3K
Mike James
Mike James@focker13·
his major point was overall there was a larger placebo effect than the drug had but if you look at the PD cases that had progressed further 3+ years there was almost no placebo effect and the drug worked wonders. Seems pretty silly to only focus on the overall data, the 3yr + had 158 participants…
English
0
0
2
136
Anders
Anders@Anders_Research·
@AaronRosenblum5 Translation: the 20mg group improved by 3 points on UPDRS Part III across the entire ITT study, regardless of time since diagnosis, and there was a highly unexpected placebo response across the entire study. Good analysis.
English
1
0
2
700
Aaron Rosenblum, PhD, former CFA (fuck dues)
$anvs did not disclose it directly but in the <3 subgroup (2/3 of study) placebo got better and high dose got worse for part 2, while placebo got way better (4.5 pts) on part 3 while high dose only improved by 3 pts..
Aaron Rosenblum, PhD, former CFA (fuck dues) tweet mediaAaron Rosenblum, PhD, former CFA (fuck dues) tweet media
English
8
3
25
25.9K
Adam Feuerstein ✡️
Adam Feuerstein ✡️@adamfeuerstein·
$ANVS The Parkinson's study failed. Of course, it did. And of course, the company is claiming positive results based a post-hoc subgroup analysis.
English
21
6
67
23.6K
Mike James
Mike James@focker13·
@adamfeuerstein @MattNachtrab $SAVA obviously increases cognition for some people based on phase 2 data alone, your certainty is either incomplete or evil..
English
0
0
1
282
Adam Feuerstein ✡️
Adam Feuerstein ✡️@adamfeuerstein·
How was your weekend? @MattNachtrab spent his weekend panic tweeting about $SAVA. I’m not a vindictive person, but I’ll make an exception here. Matt’s role as leader of the Cassava-Wang goon squad has blown up in his face. His humiliation and his anguished screams for help are a joy to watch. I hope everyone who’s been a target of his vile abuse all these years is enjoying it as well.
English
40
8
102
36.9K
Sp3cul8r
Sp3cul8r@sp3cul8r·
@SToTheT1 I’d really like to see $FRC and $USB stock prices firm up. Those two are worrying me a bit. Wtf could be going on at $USB ?
English
1
0
0
290